Angle, an AIM-listed specialist medtech company, has initiated the launch of its Parsortix non-invasive cancer diagnostic product for the research market.

The product is based on taking a blood test, and the system either counts circulating tumour cells (CTCs) in the blood or captures and recovers the CTCs as a "liquid biopsy" for molecular analysis of the cells.

To accelerate deployment of the Parsortix system, Angle is in the process of placing machines on loan with a limited number of key users worldwide. The key users' research work will contribute to the data sets that Parsortix is developing to support regulatory submissions for marketing and Food and Drug Administration approval.

Andrew Newland, the founder and Chief Executive of the group, said: "Launch of the Parsortix system in the research market is a key milestone moving the business from the development stage into commercialisation. We are now intending to move rapidly to establish some key collaborations with leading cancer research groups."

The share price rose 15.79% to 66p by 13:50.

NR

Related share prices
Angle (AGL) share price